Clinical Trial Update: Arsenic Trioxide in Treating Patients With Relapsed or Refractory Lymphoma or Leukemia [NA]

View source ↗

Summary

A clinical trial evaluated arsenic trioxide in patients with relapsed or refractory lymphoma and leukemia; the study status is terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
• Follicular Lymphoma
• Nodal Marginal Zone B-cell Lymphoma
• Prolymphocytic Leukemia
• Small Lymphocytic Lymphoma
• Splenic Marginal Zone Lymphoma
• Waldenström Macroglobulinemia

Drugs mentioned

• Arsenic Trioxide (arsenic trioxide)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma | NA | Status: TERMINATED